IBRX | tickerfilter.com

Fundamental analysis

53%

Profitability 43%

Dept financing 43%

Liquidity 75%

Performance 60%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

13.10%

1 Month

-12.77%

3 Months

18.50%

6 Months

236.07%

1 Year

226.69%

2 Year

65.99%

Key data

Stock price

$8.10

P/E Ratio

0.00

DAY RANGE

$7.98 - $8.56

EPS

-$0.38

52 WEEK RANGE

$1.83 - $12.43

52 WEEK CHANGE

$204.83

MARKET CAP

1.950 B

YIELD

N/A

SHARES OUTSTANDING

1.028 B

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-11-2025

BETA

2.82

PUBLIC FLOAT

AVERAGE 10 VOLUME

$15,162,880

AVERAGE 30 VOLUME

$21,841,606

Company detail

CEO: Richard Adcock
Region: US
Website: immunitybio.com
Employees: 590
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.

IBRX - ImmunityBio, Inc.